Tuesday, February 9, 2016

Indian Equity Market:Metal:Updated on 13th September: Steel Sector Tata Steel:

13th Sept.2016:- Tata Steel:
Q1-2016 Loss Rs.3183/-Crores.
SWOT analysis of Tata Steel Proposed Effective Restructuring of its Foreign Business::-

Strengths:- Very Good Plants in 

·         Port Talbot,

·         Netherland,

·         Speciality Steel in Yorkshire,

·         and Pipe Mills in Hartle Pool.

Weaknesses :- High Cost of running Plants and British Steel pension Fund,

 Opportunities:-For Ist Two Plants possibility of 50:50 Joint Venture Between  Tata Steel & Thyssen Krupp Germany.

Proposed 25% Investment by British Government.

Purchase of Last Two Plants by Mr Sanjeev Gupta Indian Origin Business Man of UK.

Threats :- To explore Possibility of Cost Reduction by 100 Million Pound.
Suitable outcome for British Steel Pension Scheme1.30 Lac Members and deficit Pound 70Crores. Discussion with British Trade unions.
Total Borrowings:-Rs.75259/- Crores as on 30th June 2016: Rs.71798/-Crores including European Business Rs.22500 /- Crores.



10th July 2016:-
A.Buy back of Shares by Coal India Ltd is a certainty: The Successful completion of Shares by Seven subsidiaries have resulted in Huge Cash in the Hands of Coal India Ltd. and available for buy back of its own Shares. 


2nd June 2016:- Coal India Ltd.(CIL) has increased its Product prices by 5%. CIL share has picked up on BSE.

24th May 2016:-
Coal India Ltd.:-  This Share is now totally bottomed out. At Current Valuation the Share is strongly recommended to Purchase.

24th May 2016:

Buy Tata Steel at around Rs.325/-
Earlier News:-
Tata Steel is still favourite of Bourses at Current of Rs345/- the Share Seems Attractive. Target is Rs.400/- 
MIP to provide temporary relief to steel industry:
Other Factors are also Counting:-
  1. Adverse demand-supply equation that the Steel industry is likely to face in the short to medium term, it said. 
  2. Poor Demand Growth:- India's steel consumption growth improved driven by automobile and construction sectors. 
 Tata Steel saw its consolidated net profit during April-December 2015 shrink to one-tenth of what it was a year ago. With its overseas operations facing headwinds too, the company booked an impairment charge of over 7,900 crore on its European business in the September quarter.
 
There is an inverse correlation between the prices of the US dollar and commodities.
With dollar index peaking, sectors like metals, mining may outperform Defensives  

Moderation in the US dollar is usually positive for Indian equities and currency. 
The fall in the dollar may lead many investors to increase their allocation to cyclical stocks than to defensive stocks.
MIP 'game changer' for steel;
The government has decided to impose a minimum import price for steel products, something that is likely to make import prices of the alloy costlier than local prices. What does this mean for Indian companies?
 The government has decided to impose a minimum import price for
    steel products, something that is likely to make import prices of
    the alloy costlier than local prices. What does this mean for Indian
    companies?
It is a bold move, a minimum import
price (MIP) for steel products that is likely to make many imported
steel products costlier than domestic ones. This comes following months
of complaints from steel companies that cheap Chinese imports were
undercutting Indian steel companies and hitting their margins.
Following the decision, the MIP for hot rolled coil (HRC) steel has been
set at USD 450 per tonne, which would result in a landed price of about
USD 600 per tonne after customs and safeguard duty. The ruling domestic
price of HRC steel is about USD 500 per tonne, something that will
likely move up around or before the government's MIP directive comes
into effect on March 1.
It is the first time in 15 years the country has imposed MIP -- and said it would give a much needed shot in the arm to local steel companies,
which have suffered from over a year of falling prices.

Wednesday, February 3, 2016

Indian Finance: Updated on 2nd Aug. 2016:SMILE-Soft Loan for MICRO,SMALL & MEDIUM ENTERPRISE: MUDRA Small Bank Loans for Traders, Cottage Industries and Retailers under various Bank Schemes Ranging from Rs.10Lacs to Rs.1Crore


For Expansion,Modernization & Technological upgradation to MSME sector. Manufacturing & Processing companies.

  1. Repayment period 7 years
  2. For Soft Loan Interest Rate for 3 yrs.9.35
  3. Term Loan Interest Rate 9.45 to 9.95 period is Three years only. 
  4. After Three years Normal Rate of Interest.
Reg. Ensuring Lower Cost of Funding . Offering of Services as Free-Lance CFO:  Assignment on Hourly/ Retainer-ship basis: 
May I take liberty to encroach upon your valuable time to help you in a systematic Manner: so that Bankers understand your Business Plans . To, ensure Good valuation for Funding through Regular & Systematic Steps in right direction as follows:-    
A. Books of Accounts:-
  1. At present Govt. of India has sponsored various Bank Loan Schemes without Collateral. For That a detailed review of Current Operation is required.
  2. Recognize Business Strengths Concentrate on the same & would definitely get Finance. 
  3. Strong Management Information System created out of Streamlined Processes, supported by Budgeting & Performance Measurement & Monitoring. 
Timely reporting with desired compliance and Crystal Clean Books of Accounts. It would ensure greater visibility of operating Parameter.Visibility of Operations Performance is very vital for the organization:
Keeping Accounts ready always. Maintaining Confidentiality of All Sensitive-  Documents and Agreements. Compliance, Process-Management. 
  1. MUDRA:- Loan under this Scheme are without any Collateral.
    Small entrepreneurs under the Pradhan Mantri Mudra Yojana,  developing "personal sector" to become self-sufficient, start businesses and generate new employment avenues..
    Loans between Rs. 50,000 and Rs. 10 lakh are provided to small entrepreneurs.
    The Micro Units Development and Refinance Agency Ltd (MUDRA) focuses on the 5.75 crore self-employed who use funds totalling Rs. 11 lakh crore and provide jobs to 12 crore people.The banking sector has been allocated an overall disbursement target of
    about Rs. 1.22 lakh crore during 2015-16 for Mudra loans.
    D.MUDRA Yojana will be refinance for lending to micro businesses/units.
    1. Shishu: covering loans upto Rs. 50,000/-
    2. Kishor: covering loans above Rs. 50,000/- and upto Rs. 5 lakh
    3. Tarun: covering loans above Rs. 5 lakh and upto Rs. 10 lakh
    Businesses/entrepreneurs/units covered would include:-
    1. Proprietorship/partnership firms running as small manufacturing units, Shopkeepers, Fruits/Vegetable Sellers, hair cutting saloon, beauty parlours, transporters, truck operators, hawkers, co-operatives or body of individuals, food service units, repair shops, machine operators,small industries, artisans, food processors, self help groups, professionals and service providers etc. in rural and urban areas with financing requirements upto Rs 10 lakh.
    2. Sector/activity specific schemes, such as schemes for business activities in Land Transport, Community, Social & Personal Services,Food Product and Textile Product sectors. Schemes would similarly be added for other sectors / activities.
    Schemes:-
    1. Micro Credit Scheme (MCS)
    2. Refinance Scheme for Regional Rural Banks (RRBs) / Scheduled
    Co-operative Banks
    3. Mahila Uddyami Scheme
    4. Business Loan for Traders & Shopkeepers
    5.Missing Middle Credit Scheme
    6. Equipment Finance for Micro Units

For more details please contact undersigned.
With Warm Regards,
                  Ashok Agarwala
                                                      7228805981

    Saturday, January 16, 2016

    Indian Equity Market: Up dated 16th Sept.16:Lower Revenue for Indian I.T. Cos.: facing Volatile Macro Economic Conditions-World over:



    16th Sept.2016:-
    Post Brexit: Volatile Macroeconomic Conditions in Europe.
    Lower Revenue Expected for IT Comapnies: Main Reasons are:-
    Main Dependance are on U.S. and U.K.
    Decline in consulting Business.
    In India Finacle and other BFSI is showing declining trend.
    High Foreign Currency Fluctuations,
    Large Deals even though finalized, taking more time than expected to take off/Complete. Immenient uncertainty has compelled Clients World over to delay IT Projects & reduce discretionary spendings.
    US Federal Reserve keeping its Interest Rate at Record low
    Hence earlier recommendation of 15th July 2016 is not continuing.
    15th July2016:
    Strong Recommendation for Continuing with TCS &Infosis.




    TCS Q4 revenue growth marginally beats expectations










    TCS rated world's most powerful brand in IT Services: Report

    Scoring highly on a wide variety of measures such as familiarity,

    loyalty, staff satisfaction and corporate reputation, Tata Consultancy

    Services (TCS) emerged as the IT services industry's most powerful brand

    with a score of 78.3 points earning it an AA+ rating has been rated as the world's most powerful brand in Information Technology Services by a leading global brand valuation firm, Brand Finance's 2016 annual report evaluated thousands of the world's top brands to determine which are the most powerful and the most valuable. "TCS' customer focus has been central to its recent success, but a

    closer look at our data shows strong and improving scores for brand

    investment and staff satisfaction too," said David Haigh, CEO, Brand

    Finance. "It has emerged as a dominant force in the IT services industry and is the strongest brand in the sector. Its brand power is indisputable,"Haigh said.According to the report, TCS is also the fastest growing brand within its industry over the last 6 years. The company's overall brand value has increased from USD 2.34 billion in 2010 (when the first evaluation of the TCS brand was conducted) to USD 9.4 billion in 2016. The efforts of our 344,000 employees

    our best brand ambassadors have helped our brand strength to be rated at
    the top of our industry," said N Chandrasekaran, CEO and Managing
    Director of TCS.
     

    1. Growth from outsourcing becomes harder to generate or the erstwhile levels of growth from outsourcing becomes harder to generate, 
    2.  In this volatile Market Choose TCS and HCL Tech are recommended.
    * Second-largest software firm Infosys today

     Aikido services, bringing the power of intelligent systems,
    automation and software to amplify the skills and imaginations of our people," 
    Share Price Rs 1,126.55          


    Particulars Period   F.Y.   Rs.Crores   Revenue       Net Profit


    Liquid Assets         31.12.15                            31526                          

                                 30.09.15                            32099

    Quarter ending       31.12.15                                                         US$240 Crore         US$ 52.40 Crores

                                 31.12.15                                                          Rs.15902 Crore       Rs.3465 Crores
                                                                                                                          
    Quarter Ending      30.09.15                                                         Rs.15635 Crores       Rs.3398 Crores

    Quarter ending      31.12.14                                                         Rs.13796Crores        Rs.3250 Crores
    Revenue                                                                                                    

    Current fiscal constant Currency Revenue guidance upwards to 12.8-13.2 per cent.





    B.Analysis of3rd Quarter Results of TCS Mumbai-:
    1. Revenue rose just 0.5% sequentially,if exchange rate fluctuations were eliminated, and shrank 0.3% otherwise.
    2. The third-quarter performance makes it unlikely that the nation's top software exporter will beat Nasscom's industry growth guidance of 12-14%for fiscal 2016.  TCS
    3. IT spending to shrink as much as 5.5% in 2015.volatility, uncertainty and an adverse currency.
    4. TCS' revenue for the quarter rose 0.5% sequentially to $4.14 billion in constant currency terms. On the same basis, and after factoring in the impact of the floods, analysts on average had expected about 0.8% growth. In rupee terms, TCS reported sequential revenue growth of 0.7% to Rs 27,364 crore. Profit after tax was flat at $926 million. In rupee terms, the net profit rose 0.9% sequentially to Rs 6,109 crore. Operating margin contracted 0.48 percentage point to 26.6%.
    5. Digital, one of the bright spots for the company in the recent past,also slowed.
    6. Revenue from India, which contributes about 6% to the total,fell 6.7% sequentially. Revenue from international markets grew 1.1% sequentially.
      North America, which accounts for 53.5% of revenue, grew 1.4% sequentially, but in the UK, a market that contributes about 16%, revenue fell 0.7%. 
    7. Most of the UK contraction has been attributed to the continuing weakness in TCS' insurance platform, Diligenta. "still need a quarter before Diligenta bottoms out. Business demand and order inflow remains intact
    8. Rival Accenture, which recently reported results for its fiscal first quarter ended November 30, posted double-digital growth in its digitalbusiness

    C.Wipro quarter ended December 31

    In-line with Analyst Expectations.


    "A pick-up in large deal closures led by Global Infrastructure Services. 
    Customers want to simplify operations, optimize their IT spend while investing in Digital to transform their business & are well-positioned ,"


    *Net profit: *

    Quarter ended 
    December 31, 2015,           December 31, 2014
    Rs. 2,234 crore              Rs. 2192crore

    Increase of around 2% year-on-year.

    *Dividend:*

    Interim dividend of Rs.5 per equity share of par value Rs.2/- each

    *Outlook for March Quarter - Guidance:*

     IT Services business to be in the range of $ 1,875 million to $1,912 million. 

    Expectation for Next Financial Year.

    *IT Services Segment: *

      • IT services segment Profit rose to Rs 2,480 crore ($375 million), while margins stand at 20.2%.
      • IT services segment Non-GAAP constant currency revenue in dollar terms grew 1.4% sequentially and grew 6.3% YoY.  
      • Headcount of 170,664 
      • Added 39 new customers during the quarter.

    *Large deals:*

    Signed a Definitive agreement to acquire Viteos Group, a BPaaS provider for Alternative Investment Management Industry.

    Winning Large Deals globally  Wipro has entered into a multi-year global infrastructure support engagement with one of the largest medical devices companies in the world.

    Standardization & Simplification:-  Wipro will standardize and simplify the customer's IT infrastructure across multiple service lines and in over 90 countries.

    "Acquisition:-During the quarter, competitive differentiation BY Acquisition of Two high-potential companies - Cellent and Viteos,"

    "Business Continuity Plans:-Impact of Chennai floods minimized significantly by strong execution of our robust Business Continuity Plans (BCP). The additional expenses incurred in deploying BCP impacted


     

    Monday, November 2, 2015

    Indian Equity: Pharma11.10.16: Consolidation/Fresh Entries in Pharma Shares:Piramal Acquisition of-5Anaesthesia&Pain-Mgmt.brands from Janssen Pharma AND IPO-Rs.2000 Crore (US$300Million) from Eris Lifesciences:


    ________________________________________________
    October10,2016:-Front Page News:-
    Eris is only( From-2007) 10yrs old, owned by Mr Amit Bakshi: 
    Entering in Public Issue Market 
     Private Equity Firm Chrys Capital having 16.25% holding is ready for Multi Bagger exit.
    Listing through Offer for Sale Route(OFS) during Next Calender yr 2017:
    Financial Indices:Net Proit- 26%
                                EBITDA- 44%
                                ROC-     140%

    Very High Stafff Productivity Rs.5Lac per Month(PCPM).

     Products in Chronic Life Style ailments like Diabiteic and High Blood Pressure.
    Other Therauptic Segments r Cardilogy,Gasteroenterology,Orthopaedics,Paediatrics.

    25 Brands Contributing 92% Revenue.

    Recent introduction in Polycystic Ovarian Syndrome(PCOS): Lifestyle disorder in Women of  Reproductive Age.

    No Export.

    Tough Competition from Lupin, Cadila & Sun Pharma.
    _________________________________________________________________________________
    • June22,2016:-New FDI policy in Pharma Industry:-
    74% FDI allowed for Acquisition, Merger and Amalgamation.
    •  The Latest news is that Mr Rakesh Jhujunwala has recommended Pharma Industry as a very good Long Term Investment. Base of Recommendation are as under:-
    • Indian pharma supplies 40 per cent of American generics and has 7 per cent of value. If this 40 per cent is to be 50 per cent and we have to go up the value chain, what is going to happen?  Indian costs are very very low, Indian companies are getting size, Indian entrepreneurs have understood the market. Why will this company not grow and the whole market has an absolute lottery.
                                    Price           Market Cap 
    *Cadila Healthcare: Rs317/-      Rs.32000/- Crores
    Problem of warning letter of US business
    *Torrent Pharma: Rs.1317/-       Rs22000 Crores
    The US plants have clean FDA status and stable India business accounts for half of the profits.
    *Ipca Laboratories: Rs.496/-      Rs6300/-Crores
    Resolution in US post warning letter?

    *GSK Consumer Healthcare: Rs.5815/-        Rs.24400Crores 
    *Lupin: Rs.1461/-                                       Rs.65900/-Crores
    Generic drugs such as gFortamet and gGlumetza offer strong near-term earnings support,Lack of competition, strong demand for gFortamet. Low regulatory concerns, less exposure to adverse currency movements are key positives.
    high opportunities in the US, increased consumption in
    India, more opportunities in Japan which will be key drivers to support

    growth.

    Lupin:-Products like Gulmetza, Gavis Portfolio, and Steep Price hike expected in Fortamet. 

    Aurobindo: Rs.727/-                                 Rs.42600Crores
    Aurobindo now has a total of 224 ANDA approvals (196 final approvals, including 10 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
    The promoters holding in the company stood at 53.92 per cent while institutions and others held 34.97 per cent and 11.11 per cent, respectively







    Aurobindo Pharma received USFDA’s approval to manufacture and market Loperamide Hydrochloride tablet and Methylprednisolone Sodium Succinate injection used for treating diarrhoea and allergy.

    Dr Reddy:- The Product NEXIUM expected to contribute EPS Rs24/- in coming Two Three years.
      Benefiting from its leading position in the bio-similars market is Dr Reddy. In 2007, Dr Reddy the first to launch a bio similar to Roche cancer drug Rituximab (Rituxan), and has four other biosimilars on the market. The company drug characterization strategy and quality measures give Dr Reddy a significant competitive advantage
    that reduces the uncertainty of potential outcome differences



    Overall Scenario:-
    The pharmaceuticals market in India, valued at $ 20 billion in 2015, is set to soar to $ 55 billion by 2020,representing an impressive compound annual growth rate (CAGR) of 22.4 percent, according to the UK-based research and consulting firm Global Data. India’s rapidly growing generics market is the primary driver of the nations pharmaceutical with sales expected to soar by nearly 84 percent to $ 26.1 billion in 2016. Generic drugs, with their low costs and easy accessibility, now dominate India pharmaceutical space, accounting for around 70 percent of the market.

    Adam Dion, senior industry analyst, Global Data, said, India supplies 20 percent of global generic medicines in terms of export volume, making the country the largest provider of generic medicines globally. Indeed, Indian pharmaceutical companies are now exporting to countries like Brazil, Mexico, South Africa, Russia and Japan, and,

    according to India Ministry of Commerce and Industry, the nation pharmaceutical export segment has more than doubled from $ 7.8 billion in 2008 to $ 16.5 billion in 2014.

    Another driver of India’s pharmaceutical sector is the potentially lucrative bio-similar market, which is expected to increase to $40 billion globally by 2020, as biologic treatments are introduced fordiseases such as diabetes, cancer, multiple sclerosis, and rheumatoidarthritis.
    in patients, explained Dion.